Please login to the form below

Not currently logged in
Email:
Password:

Roche sues Dr Reddy's over Boniva for osteoporosis

Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of osteoporosis drug Boniva

Swiss-based pharmaceutical company Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of Roche's osteoporosis drug Boniva (ibandronate).

The complaint was filed on 20 September in a New Jersey court. Roche says that Boniva is covered by patents running from 2012 to 2023.

In a statement, Roche said: "This action arises because of Dr Reddy's efforts to gain approval from the FDA to market a generic copy of Roche's Boniva once-monthly drug product prior to the expiration of Roche's patent rights covering it."

Earlier in September, Roche initiated legal action against Israel-headquartered generics giant Teva Pharmaceutical's move to enter the US market with a Boniva copy.

Boniva, which is sold under the name of Bonviva in the EU, racked up sales of CHF 488m in FY06.

25th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics